MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1371/journal.pone.0310229

Медицинская библиотека · PloS one · 2025

A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901 (NeuroAiDTMII) for the treatment of cognitive impairment after mild traumatic brain injury.

Pilipenko Pavel I, Ivanova Anna A, Kotsiubinskaya Yulia V, Grigoryeva Vera N, Khrulev Alexey Y, Skorokhodov Anatoly V, Gavrik Maxim M, Mkrtchan Nona N, Majdan Marek, Valkovic Peter, Rabarova Daria, Barker-Collo Suzanne, Jones Kelly, Feigin Valery L

СтатьяРандомизированное исследованиеМногоцентровое исследованиеКлиническое исследование III фазыПеревод в очереди

Аннотация

INTRODUCTION

About half of the world population will suffer from a traumatic brain injury (TBI) during their lifetime, of which about 90% of cases are mild TBI. Although up to 40% of adults with mild TBI experience persistent functional deficits, there is no proven-effective treatment to facilitate recovery after it.

METHODS AND ANALYSIS: This randomized placebo-controlled multi-centre study was aimed to examine the efficacy of herbal supplement MLC901 on complex attention following mild TBI at 6 months post-randomisation, as a primary outcome measured by CNS Vital signs (CNS-VS). Adults aged 18-65 years, who were 1-12-months post-mild TBI and experienced cognitive impairment, were randomly assigned to receive either MLC901 two capsules (0.4g/capsule) or placebo three times a day for 6 months using centralized stratified permuted block randomization. Secondary outcomes: Rivermead Post-Concussion Symptoms Questionnaire (RPQ; neurobehavioral sequelae); Health Related Quality of Life (QOLIBRI); Hospital Anxiety and Depression Scale (HADS); and safety. Mixed effects models of repeated measures with intention to treat analysis were employed. A Least Square Mean Difference (LSMD) from baseline to 3-, 6-, and 9-month follow-up was calculated with 95% confidence intervals (CI).

RESULTS

In the analysis, 182 participants (47.8% females) were included. Multivariable mixed effects model analysis did not reveal significant improvements in complex attention (LSMD = -1.18 [95% CI -5.40; 3.03; p = 0.58]) and other cognitive domains at 6 months in the MLC901 group compared to the Placebo group. There were significant improvements in RPQ, QOLIBRI, anxiety and depression in the MLC901 group compared to the Placebo group at 6 and 9 months (LSMD -4.36 [-6.46; -2.26] and -4.07 [-6.22; -1.92], 4.84 [1.58; 8.10] and 3.74 [0.44; 7.03], -1.50 [-2.29; -0.71 and -0.96 [-1.84; -0.08], -1.14 [-1.92; -0.35] and -1.14 [-1.94; -0.34]), respectively. MLC901 tested was proven safe.

CONCLUSIONS

Although the 6-month treatment with MLC901 did not result in a statistically significant difference with placebo for CNS-VS measurement of cognitive domains in individuals with mild TBI, the study showed a clinically and statistically significant improvement in all clinical scales assessed by the investigators.

TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT04861688.

Для цитирования: Pilipenko Pavel I, Ivanova Anna A, Kotsiubinskaya Yulia V, Grigoryeva Vera N, Khrulev Alexey Y, Skorokhodov Anatoly V, Gavrik Maxim M, Mkrtchan Nona N, Majdan Marek, Valkovic Peter, Rabarova Daria, Barker-Collo Suzanne, Jones Kelly, Feigin Valery L. A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901 (NeuroAiDTMII) for the treatment of cognitive impairment after mild traumatic brain injury.. PloS one. 2025. DOI: 10.1371/journal.pone.0310229.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.